Improvement in long-term ECMO by detailed monitoring of anticoagulation: A case report

Perfusion

Volumn 26, Issue 1, 2011, Pages 59-64

  Sievert, Alicia ^a   Uber, Walter ^a   Laws, Stacey ^a   Cochran, Joel ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

activated clotting time; anti Xa unfractionated heparin; anticoagulation; antithrombin III; extracorporeal membrane oxygenation

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 8; FENTANYL; FIBRINOGEN; HEMOGLOBIN; HEPARIN; MILRINONE; NITROPRUSSIDE SODIUM; VECURONIUM;

ANTICOAGULANT THERAPY; ARTERIAL GAS; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING TIME; CASE REPORT; CHILD; COUGHING; EXTRACORPOREAL OXYGENATION; FEMALE; FEVER; HUMAN; INFERIOR CAVA VEIN; INFLAMMATION; INFLUENZA A; INFLUENZA B; MONITORING; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PLEURA EFFUSION; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY DISTRESS; TACHYPNEA; THROMBOSIS; THROMBUS;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; DRUG MONITORING; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT; PARTIAL THROMBOPLASTIN TIME;

EID: 78650670935     PISSN: 02676591     EISSN: None     Source Type: Journal    
DOI: 10.1177/0267659110385513     Document Type: Article

References (25)

1. Baird CW, Zurakowski D., Robinson B., et al. Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. Ann Thorac Surg 2007 ; 26: 231-240.
2. Sievert AN, Shackelford AG, McCall MM Trends and emerging technologies in extracorporeal life support: results of the 2006 ECLS Survey. J Extracorp Circ Tech 2009 ; 41: 73-78.
3. Haines NM, Rycus PT, Zwischenberger JB, Bartlett RH, Undar A. Extracorporeal Life Support Registry Report 2008 ; neonatal and pediatric cases. ASAIO J 2009 ; 55: 111-116.
4. Gruenwald C., deSouza V., Chan AK, Andrew M. Whole blood heparin concentrations do not correlate with plasma anti-factor Xa heparin concentrations in pediatric patients undergoing cardiopulmonary bypass. Perfusion 2000 ; 15: 203-209.
5. Chan AK, Leaker M., Burrows FA, et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost 1997 ; 77: 270-277.
6. Owings JT, Pollock ME, Gosselin RC, et al. Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques. Arch Surg 2000 ; 135: 1042-1047.
7. Bull BS, Korpman RA, Huse WM, Briggs, BD Heparin therapy during extracorporeal circulation: II The use of a dose response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg 1975 ; 69: 685-689.
8. Cheung AT, Levin SK, Weiss SJ, et al. Intracardiac thrombus: a risk of incomplete anticoagulation for cardiac operations. Ann Thorac Surg 1994 ; 58: 541-542.
9. Despotis GJ, Joist JH, Hogue CW, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995 ; 110: 46-54.
10. Newall F., Ignjatovic V., Summerhayes R., et al. In vivo age dependency of unfractionated heparin in infants and children. Thrombosis Research 2009 ; 123: 710-714.
11. Olson, JD, Arkin, CF, Brandt, JT, et al. College of American Pathologists Conference XXXI on Laboratory Monitoring of Anticoagulant Therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998 ; 122: 782-798.
12. Bates, SM, Weitz, JI, Johnston, M., et al. Use of a fixed activated partial thromboplastin time ratio to establish a therapeutic range for unfractionated heparin. Arch Intern Med 2001 ; 161: 385-391.
13. Marci CD, Prager D. A review of the clinical indications for the plasma heparin assay. Am J Clin Pathol 1993 ; 99: 546-550.
14. Muntean W. Coagulation and anticoagulation in extracorporeal membrane oxygenation. Artif Organs 1999 ; 23: 979-983.
15. Hirsh J., Raschke R., Warkentin TE, et al. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring efficacy, and safety. Chest 1995 ; 108 (suppl 4): 258S - 275S.
16. Kovacs MJ, Keeney M., MacKinnon K., Boyle E. Three different chromogenic methods do not give equivalent anti-Xa levels for patients on therapeutic low molecular weight heparin (dalteparin) or unfractionated heparin. Clin Lab Haem 1999 ; 21: 55-60.
17. Ignjatovic V., Summerhayes R., Gan A., et al. Monitoring unfractionated heparin (UFH) therapy: which anti factor Xa assay is appropriate? Thromb Res 2007 ; 120: 347-351.
18. Christensen RD Hematologic problems of the neonate. WB Saunders, Philadelphia PA, 2000 ; 1: 246.
19. Zavadil DP, Stammers AH, Willett LD, et al. Hematological abnormalities in neonatal patients treated with extracorporeal membrane oxygenation (ECMO). J Extracorp Circ Tech 1998 ; 30: 83-90.
20. Luddington RJ Thrombelastography/thromboelastometry. Clin Lab Haematol 2005 ; 27: 81-90.
21. Urlesberger B., Zobel G., Zenz W., et al. Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatrics 1996 ; 129: 264-268.
22. Chalmers E., Bonduel M. Antithrombotic therapy in children. Progress in Pediatric Cardiology 2005 ; 21: 31-43.
23. Gruys E., Toussaint MJM, Niewold TA, Koopmans SJ Acute phase reaction and acute phase proteins. J Zhejiang Univ Science 2005: 6B: 1045-1056.
24. Gabay C., Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999 ; 340: 448-454.
25. Koster T., Blann AD, Briet E., et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep vein thrombosis. Lancet 1995 ; 345: 152-155.